rHuEPO and improved treatment outcomes: Potential modes of action

Oncologist

Volumn 9, Issue SUPPL. 5, 2004, Pages 41-47

  Blackwell, Kimberly ^a   Gascón, Pere ^b   Sigounas, George ^c   Jolliffe, Linda ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c EAST CAROLINA UNIVERSITY   (United States)

^d Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

Anemia; Cancer; Epoetin alfa; Hemoglobin; Mechanism of action; Outcomes; Quality of life; RHuEPO; Survival; Tumor hypoxia

Indexed keywords

ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN;

AMNESIA; ANEMIA; ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; COGNITIVE DEFECT; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; FATIGUE; GENE CONTROL; HUMAN; HYPOXIA; METASTASIS; MULTIPLE MYELOMA; OXYGENATION; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME;

ANEMIA; ANIMALS; CELL HYPOXIA; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; ERYTHROPOIETIN, RECOMBINANT; FATIGUE; HUMANS; MICE; MULTIPLE MYELOMA; NEOPLASMS; QUALITY OF LIFE; RADIATION TOLERANCE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 10644243589     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-90005-41     Document Type: Conference Paper

References (71)

1. Mercadante S, Gebbia V, Marrazzo A et al. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000;26:303-311.
2. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001;28(suppl 8):7-14.
3. Girinski T, Pejovic-Lenfant MH, Bourhis J et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989;16:37-42.
4. Dische S. Radiotherapy and anaemia - the clinical experience. Radiother Oncol 1991;20(suppl 1):35-40.
5. van Acht MJ, Hermans J, Boks DE et al. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 1992;23:229-235.
6. Tarnawski R, Skladowski K, Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys 1997;38:1007-1011.
7. Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol 1998;174(suppl 4):31-34.
8. Lee WR, Berkey B, Marcial V et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:1069-1075.
9. Grogan M, Thomas GM, Melamed I et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-1536.
10. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(suppl 8):49-53.
11. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
12. Antonadou D, Cardamakis E, Sarris C et al. Effect of the administration of recombinant human erythropoietin in patients with pelvic malignancies during radiotherapy. Radiother Oncol 1998;48(suppl 1):S122.
13. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425.
14. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;199:2875-2882.
15. Glaser CM, Millesi W, Kornek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-715.
16. Littlewood TJ, Bajetta E, Mortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
17. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: erythropoietin has multiple actions. STEM CELLS 2002;20:485-492.
18. Shasha D. The negative impact of anemia on radiotherapy and chemoradiation outcomes. Semin Hematol 2001;38(suppl 7):8-15.
19. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-276.
20. Vaupel P, Briest S, Höckel M. Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wein Med Wochenschr 2002;152:334-342.
21. Lavey RS. Clinical trial experience using erythropoietin during radiation therapy. Strahlenther Onkol 1998;174(suppl 4):24-30.
22. Lavey RS, McBride WH. Influence of hematocrit on tumor oxygenation and sensitivity to radiation. Eur J Cancer 1993;29A(suppl 6):S216.
23. Kelleher DK, Mattheinsen U, Thews O et al. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996;56:4728-4734.
24. Kelleher DK, Thews O, Vaupel P. Can erythropoietin improve tumor oxygenation? Strahlenther Onkol 1998;174(suppl 4):20-23.
25. Vaupel P, Thews O, Kelleher DK et al. Oxygenation of human tumors: the Mainz experience. Strahlenther Onkol 1998;174(suppl 4):6-12.
26. Vaupel P, Mayer A, Briest S et al. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 2003;63:7634-7637.
27. Becker A, Stadler P, Lavey RS et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;46:459-466.
28. 2 during early radiotherapy in cervical cancers: improved local control in primarily hypoxic tumors with " reoxygenation" and the impact of hemoglobin. Int J Radiat Oncol Biol Phys 1999;45(suppl 1):364.
29. Harrison LB, Chadha M, Hill RJ et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. The Oncologist 2002;7:492-508.
30. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J Clin Invest 2000;106:809-812.
31. Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. Microsc Res Tech 2002;59:41-48.
32. Rofstad EK, Danielsen T. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. Br J Cancer 1998;77:897-902.
33. Rofstad EK, Danielsen T. Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br J Cancer 1999;80:1697-1707.
34. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000;76:589-605.
35. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001;11:293-299.
36. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104-8109.
37. Ryan HE, Lo J, Johnson RS. HlF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 1998;17:3005-3015.
38. Kung AL, Wang S, Klco JM et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 2000;6:1335-1340.
39. Giantonio BJ, Levy D, O'Dwyer PJ et al. Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as frontline therapy for advanced colorectal cancer (advCRC): results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. Proc Am Soc Clin Oncol 2003;22:255.
40. Stüben G, Pöttgen C, Knuhmann K et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003;55:1358-1362.
41. Stüben G, Thews O, Pöttgen C et al. Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 2003;179:620-625.
42. Stüben G, Thews O, Pöttgen C et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-350.
43. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-1361.
44. Thews O, Koenig R, Kelleher DK et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752-756.
45. Kelleher DK, Thews O, Vaupel P. Modulation of tumor oxygenation and radiosensitivity to erythropoietin. In: Vaupel P, Kelleher DK, eds. Tumor Hypoxia. Pathophysiology. Clinical Significance and Therapeutic Perspectives. Stuttgart, Germany: Wissenschaftl Verlagsgesellschaft, 1999:39-46.
46. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999;73:280-284.
47. Harrison L, Blackwell K, Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy. The Oncologist 2004;9(suppl 5):31-40.
48. Henke M, Guttenberger R, Barke A et al. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 1999;50:185-190.
49. Lavey RS. Clinical trial experience using erythropoietin during radiation therapy. In: Vaupel P, Kelleher DK, eds. Tumor Hypoxia. Pathophysiology, Clinical Significance and Therapeutic Perspectives. Stuttgart, Germany: Wissenschaftl Verlagsgesellschaft, 1999:99-105.
50. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
51. Blohmer JU, von Minckwitz G, Paepke S et al. Sequential adjuvant chemo-radiotherapy with vs. without erythropoietin for patients with high-risk cervical cancer-second analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Proc Am Soc Clin Oncol 2002;21:206a.
52. Ludwig H. rHuEPO and treatment outcomes: the preclinical experience. The Oncologist 2004;9(suppl 5):48-54.
53. Hudis CA, Van Belle S, Chang J et al. rHuEPO and treatment outcomes: the clinical experience. The Oncologist 2004;9(suppl 5):55-69.
54. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699.
55. Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992;87(suppl 1):4-11.
56. Leitgeb C, Pecherstoifer M, Fritz E et al. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoictin. Cancer 1994;73:2535-2542.
57. Fallowfield L, Gagnon D, Zagari M et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002;87:1341-1353.
58. Cella D, Zagari MJ, Vandoros C et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003;21:366-373.
59. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
60. Curt GA, Breitbart W, Cella D et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. The Oncologist 2000;5:353-360.
61. Vogelzang NJ, Breitbart W, Cella D et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(suppl 2):4-12.
62. Brezden CB, Phillips KA, Abdolell M et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695-2701.
63. Olin JJ, Cognitive function after systemic therapy for breast cancer. Oncology (Huntingt) 2001;15:613-618; discussion 618, 621-624.
64. O'Shaughnessy J, Vukelja S, Savin M et al. Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: analysis of 6-month follow-up data. Breast Cancer Res Treat 2002;76:S138.
65. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526-10531.
66. Ehrenrcich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
67. Sigounas G, Mehlhop P, Sigounas A et al. Erythropoietin ameliorates chemotherapy-induced toxicity in vivo. Exp Hematol 2001;29:57.
68. Sigounas G, Salleng K, Mehlhop P et al. Erythropoietin inhibits drug-induced fibrosis and improves pulmonary function. Blood 2001;98:798a.
69. Musto P, Falcone A, D'Arena G et al. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis. Eur J Haematol 1997;58:314-319.
70. Mittelman M, Neumann D, Peled A et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001;98:5181-5186.
71. Dunst J. Hemoglobin level and anemia in radiation oncology: prognostic impact and therapeutic implications. Semin Oncol 2000;27(suppl 4):4-8; discussion 16-17.